Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy

Published:2019-07-23 Issue:4 Volume:322 Page:315
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Genovese Mark C.¹,Kalunian Kenneth²,Gottenberg Jacques-Eric³,Mozaffarian Neelufar⁴,Bartok Beatrix⁴,Matzkies Franziska⁴,Gao Jie⁴,Guo Ying⁴,Tasset Chantal⁵,Sundy John S.⁴,de Vlam Kurt⁶,Walker David⁷,Takeuchi Tsutomu⁸

Affiliation:

1. Division of Immunology and Rheumatology, Stanford University, Stanford, California

2. Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla

3. Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France

4. Gilead Sciences Inc, Foster City, California

5. Galapagos NV, Mechelen, Belgium

6. Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium

7. Northumbria Healthcare, North Shields, United Kingdom

8. Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/article-pdf/322/4/315/17730608/jama_genovese_2019_oi_190069.pdf

Reference24 articles.

1. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.;Singh;Arthritis Care Res (Hoboken),2016

2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.;Smolen;Ann Rheum Dis,2014

3. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.;Kalden;Nat Rev Rheumatol,2017

4. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects.;Banerjee;Drugs,2017

5. The Jak-STAT pathway in rheumatoid arthritis.;Walker;J Rheumatol,2005

Cited by 247 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

2. Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis;Clinical Rheumatology;2024-09-07

3. Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis;PLOS ONE;2024-07-31

4. JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy;International Journal of Molecular Sciences;2024-07-30

5. Assessing fatigue in women over 50 years with rheumatoid arthritis: a comprehensive case-control study using the FACIT-F scale;Frontiers in Medicine;2024-07-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3